Kigabeq

Vigabatrin, the active ingredient in Kigabeq, is an Anticonvulsant presented as an oral tablet for oral use. It treats epilepsy, including complex partial seizures and infantile spasms, in patients of various ages.

GNH USA supplies Kigabeq as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kigabeq is an antiepileptic drug that modulates GABAergic activity to control seizure disorders.

- Epilepsy: reduces the frequency and severity of generalized seizures. - Complex partial seizures: helps control focal seizure activity that originates in one brain region. - Infantile spasms: decreases the number of spasm episodes in infants with this specific seizure type.

Vigabatrin may cause a range of adverse reactions, some of which are more frequent than others.

Common Side Effects: - Drowsiness: feeling unusually sleepy or fatigued. - Dizziness: sensation of light‑headedness or loss of balance. - Headache: mild to moderate pain in the head region. - Nausea: feeling of queasiness or urge to vomit.

Serious or Rare Side Effects: - Permanent visual field loss: irreversible peripheral vision defects. - Severe depression: marked mood changes that may include suicidal thoughts. - Hepatotoxicity: abnormal liver function tests or liver injury. - Acute skin reactions: severe rash or Stevens‑Johnson syndrome.

Before initiating therapy, clinicians should consider several safety measures.

- Visual monitoring: perform baseline and periodic visual field testing. - Renal function: assess kidney health as the drug is renally excreted. - Psychiatric assessment: monitor for signs of depression or suicidal ideation. - Pregnancy risk: evaluate benefits versus potential fetal risks; data are limited. - Discontinuation: avoid abrupt cessation to reduce seizure rebound. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Vigabatrin can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Other GABAergic agents (e.g., benzodiazepines): may increase central nervous system depression. - Valproic acid: can raise vigabatrin plasma concentrations. - Carbamazepine: may reduce vigabatrin efficacy.

Moderate Interactions (Monitor Closely): - Antidepressants: heightened risk of depressive symptoms. - Antihistamines: additive sedation. - Oral contraceptives: possible reduction in hormonal effectiveness.